Research
Hormonal
Tirzepatide, a dual GLP-1/GIP receptor agonist, achieves up to 22.5% mean weight loss in phase 3 obesity trials.
Tirzepatide is a dual-acting hormone medication (GLP-1/GIP) that can lead to up to 22.5% weight loss in clinical trials, surpassing single-agonist GLP-1 drugs. It is available for obesity management.
GoodSupportsHIGH confidence
Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials.
Why this rating
Based on phase 3 trial data.
Source
What is the pipeline for future medications for obesity?
Eka Melson et al. · International Journal of Obesity · 2024
DOI 10.1038/s41366-024-01473-y
narrative_reviewCited 286×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →